These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 23086691)

  • 21. nCounter NanoString Assay Shows Variable Concordance With Immunohistochemistry-based Algorithms in Classifying Cases of Diffuse Large B-Cell Lymphoma According to the Cell-of-Origin.
    Saad AG; Grada Z; Bishop B; Abulsayen H; Hassan M; Firpo-Betancourt A; Teruya-Feldstein J; Fraig M; El Jamal SM
    Appl Immunohistochem Mol Morphol; 2019 Oct; 27(9):644-648. PubMed ID: 30179888
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma.
    Knittel G; Liedgens P; Korovkina D; Pallasch CP; Reinhardt HC
    Eur J Haematol; 2016 Dec; 97(6):499-510. PubMed ID: 27526684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma.
    Li L; Xu-Monette ZY; Ok CY; Tzankov A; Manyam GC; Sun R; Visco C; Zhang M; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Wang J; Parsons BM; Winter JN; Piris MA; Pham LV; Medeiros LJ; Young KH
    Oncotarget; 2015 Sep; 6(27):23157-80. PubMed ID: 26324762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm.
    Yoon N; Ahn S; Yong Yoo H; Jin Kim S; Seog Kim W; Hyeh Ko Y
    Oncotarget; 2017 Mar; 8(13):22014-22022. PubMed ID: 28423544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas.
    Lu X; Nechushtan H; Ding F; Rosado MF; Singal R; Alizadeh AA; Lossos IS
    Blood; 2005 Apr; 105(7):2924-32. PubMed ID: 15591113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Should We Use Cell of Origin and Dual-protein Expression in Treating DLBCL?
    Riedell PA; Smith SM
    Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):91-97. PubMed ID: 29352717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microarray gene expression analysis of fixed archival tissue permits molecular classification and identification of potential therapeutic targets in diffuse large B-cell lymphoma.
    Linton K; Howarth C; Wappett M; Newton G; Lachel C; Iqbal J; Pepper S; Byers R; Chan WJ; Radford J
    J Mol Diagn; 2012; 14(3):223-32. PubMed ID: 22446084
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.
    Milhollen MA; Traore T; Adams-Duffy J; Thomas MP; Berger AJ; Dang L; Dick LR; Garnsey JJ; Koenig E; Langston SP; Manfredi M; Narayanan U; Rolfe M; Staudt LM; Soucy TA; Yu J; Zhang J; Bolen JB; Smith PG
    Blood; 2010 Sep; 116(9):1515-23. PubMed ID: 20525923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NF-kappaB down-regulates expression of the B-lymphoma marker CD10 through a miR-155/PU.1 pathway.
    Thompson RC; Herscovitch M; Zhao I; Ford TJ; Gilmore TD
    J Biol Chem; 2011 Jan; 286(3):1675-82. PubMed ID: 20947507
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival.
    Haarer CF; Roberts RA; Frutiger YM; Grogan TM; Rimsza LM
    Arch Pathol Lab Med; 2006 Dec; 130(12):1819-24. PubMed ID: 17149956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.
    Sartori G; Napoli S; Cascione L; Chung EYL; Priebe V; Arribas AJ; Mensah AA; Dall'Angelo M; Falzarano C; Barnabei L; Forcato M; Rinaldi A; Bicciato S; Thome M; Bertoni F
    J Exp Clin Cancer Res; 2021 Nov; 40(1):357. PubMed ID: 34763718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic impact of germinal center B-cell-like and non-germinal center B-cell-like subtypes of bone marrow involvement in patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Cho MC; Chung Y; Jang S; Park CJ; Chi HS; Huh J; Suh C; Shim H
    Medicine (Baltimore); 2018 Nov; 97(45):e13046. PubMed ID: 30407302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma.
    Iqbal J; Sanger WG; Horsman DE; Rosenwald A; Pickering DL; Dave B; Dave S; Xiao L; Cao K; Zhu Q; Sherman S; Hans CP; Weisenburger DD; Greiner TC; Gascoyne RD; Ott G; Müller-Hermelink HK; Delabie J; Braziel RM; Jaffe ES; Campo E; Lynch JC; Connors JM; Vose JM; Armitage JO; Grogan TM; Staudt LM; Chan WC
    Am J Pathol; 2004 Jul; 165(1):159-66. PubMed ID: 15215171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
    Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
    Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Microarray-based classification of diffuse large B-cell lymphoma.
    Poulsen CB; Borup R; Nielsen FC; Borregaard N; Hansen M; Grønbaek K; Møller MB; Ralfkiaer E
    Eur J Haematol; 2005 Jun; 74(6):453-65. PubMed ID: 15876249
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth.
    Bujisic B; De Gassart A; Tallant R; Demaria O; Zaffalon L; Chelbi S; Gilliet M; Bertoni F; Martinon F
    Blood; 2017 Apr; 129(17):2420-2428. PubMed ID: 28167662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary bone diffuse large B-cell lymphoma (PB-DLBCL): a distinct extranodal lymphoma of germinal centre origin, with a common EZB-like mutational profile and good prognosis.
    Ivanova VS; Davies J; Menter T; Wild D; Müller A; Krasniqi F; Stenner F; Papachristofilou A; Dirnhofer S; Tzankov A
    Histopathology; 2024 Feb; 84(3):525-538. PubMed ID: 37965677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High concordance of gene expression profiling-correlated immunohistochemistry algorithms in diffuse large B-cell lymphoma, not otherwise specified.
    Hwang HS; Park CS; Yoon DH; Suh C; Huh J
    Am J Surg Pathol; 2014 Aug; 38(8):1046-57. PubMed ID: 24705314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.
    Yoon SO; Jeon YK; Paik JH; Kim WY; Kim YA; Kim JE; Kim CW
    Histopathology; 2008 Aug; 53(2):205-17. PubMed ID: 18752503
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction and characterization of diffuse large B-cell lymphoma cell-of-origin subtypes using targeted sequencing.
    Trabucco SE; Sokol ES; Maund SL; Moore JA; Frampton GM; Albacker LA; Oestergaard MZ; Venstrom J; Sehn LH; Bolen CR
    Future Oncol; 2021 Nov; 17(31):4171-4183. PubMed ID: 34313135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.